An analysis of data from approximately 9,000 Belgian patients by the Agence Intermutualiste offers a new reading on the intended target. It seems that half of the patients who received Opdivo treatment (nivolumab) between 2016 and 2018 died during the year. In 2019, that percentage jumped to nearly 70%.Similar results are observed for Keytruda (pembrolizumab).
The agency also points out that almost one in ten patients died in the month following the administration of the drug, suggesting that in several cases the treatment was started when it was no longer appropriate.
Source: https://www.7sur7.be/sante/la-moitie-des-patients-belges-traites-avec-un-nouveau-medicament-contre-le-cancer-sont-morts-dans-lannee~aa8d92d7/
.jpeg)
That is terrible. They are throwing Keytruda into so many patients here in the US. I wonder what the outcome will be here.
ReplyDeleteIt is, indeed. This type of data is rarely released to the public, and unfortunately the results are not encouraging.
Delete